TOKYO, Feb 21 (Reuters) - Japan’s Daiichi Sankyo Co Ltd said on Thursday it was highly satisfied with mid-stage results for a key drug to prevent strokes and clots, and would move on to late-stage trials despite fierce competition in the field.
TOKYO, Feb 21 (Reuters) - Japan’s Daiichi Sankyo Co Ltd said on Thursday it was highly satisfied with mid-stage results for a key drug to prevent strokes and clots, and would move on to late-stage trials despite fierce competition in the field.
